Multiple primary cancer means that more that two cancers occur independently in an individual. Recently, the incidence of multiple primary cancer has increased with lengthened survival, of cancer patients, development of new diagnostic technique and increased clinical evaluation. We report a patient who had adenocarcinoma of stomach combined with squamous cell carcinoma of esophagus simultaneously.

Malaria has a wordwide incidence of more than one thousand to three thousand million clinical cases and results in approximately 200 to 300 million deaths per year. Although Korea was an endemic area of Malaria, it was nearly eradicated from the country. However, indigenous cases of malaria have been reported since 1994. Recently, we experienced a case of Plasmodium vivax infection in a resident of Seoul. A 25-year old young man who had no history of being abroad, blood transfusion nor parenteral use of drug visited our hospital due to fever and chill for 4 days. A peripheral blood smear demonstrated Plasmodium vivax infection. He was treated with hydroxychoroquine and premaquine without relapse.

Thrombohemorrhagic complications in chronic myeloproliferative disease(CMPD) including chronic myelogenous leukemia(CML) are not rare. Lower incidence of disordered hemostasis is reported in CML compared with other CMPD. The mechanism of thrombohemorrhagic complications might be a consequence of qualitative platelet abnormalites and prolonged bleeding time rather than that of thrombocytosis. Although defect of platelet function has been extensively investigated, there was no established consistent correlation between clinical bleeding and number and function of platelet. The most common site of bleeding complications in the CMPD is superficial mucosa. Bleeding in deep tissue and viscera is very unusual. We report a case of CML which developed a huge spontaneous retroperitoneal hematoma.

Serum levels of carcinoembryonic antigen(CEA) were determined in 65 patients with non-small cell lung cancer to investigate the correlation with clinico-pathologic characteristics. The most common histologic type was sdenocarcinoma(44.6%), followed by sqaumous cell carcinoma(41.5%) and large cell carcinoma(9.2%). Many patients were in unresectable advanced stage(IIIB : 21.5%, IV : 46.2%). Serum CEA was positive(defined as>10ng/ml) in 28 patients(43.1%). The positivity of Serum CEA was signigicantly higher in adenocarcinoma(69.0%) than that in sqaumous cell carcinoma(25.9%) and large cell carcinoma(0.0%)(p=0.0004). There was no statistically significant difference in positivity of CEA according to stages. Serum CEA level does not seem to be seletive or specific standard tumor marker of non-small cell lung cancer patients. However, it may be useful as prognostic marker or monitor of treatment results, especially in adenocarcinoma.

The development of hypomagnesemia was investigated retrospectively in 25 patients with malignancy treated with cisplatin containing combination at the first time. Serum magnesium levels were measured 1 day after completion of cisplatin infusion. The most common type of cancer was lung cancer(9 patients) followed ny gastric cancer(5 patients), pancreas cancer, unknown prinary cancer(2 patients, respectively) and so on. EP(etoposide, cisplatin)was the most frequently administered regimen. Five patients had previous history of chemotherapy. While 10 patients received cisplatin dose of 80 mg/m²(body surface area) or more, 15 patients received less than mg/m². The mean serum magnesium concentration after chemotherapy was 1.93±0.25mg/dl(1.5-2.6mg/dl), and 8 patients(32.0%) developed hypomagnesemia(<1.9mg/sl). The incidence of hypomagnesemia showed no correlation among age of patients, dose of cisplatin, history of previous chemotherapy and regimens of chemotherapy. The serum potassium concentration after chemotherapy was not statistically different compared with that of before chemotherapy. There was no episode of symptomatic hypomagnesemia. In conclusion, hypomagnesemia is relatively common side effect of cisplatin infusion, therefore, frequent measurement of serum magnesium concentration should be mandatory in patients redeiving cisplatin containing chemotherapy.